Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2018
Poor value sees younger people dropping private health insurance
18 November 2018 - Younger people are ditching private health cover or not taking up cover in the first place, ...
Posted by Michael Wonder on 18 Nov 2018
As new therapies arrive, pressure builds on the health care system to figure out how to pay for them
15 November 2018 - The launch of a handful of inventive cell and gene therapies is already testing players in ...
Posted by Michael Wonder on 15 Nov 2018
In Michigan, Medicaid can now pay for drugs based on how well they work
14 November 2018 - The Trump administration gave Michigan’s Medicaid program permission to pay for drugs based in part on ...
Posted by Michael Wonder on 06 Nov 2018
Should a drug’s value depend on the disease or population it treats? Insights from ICER’s value assessments
6 November 2018 - The ICER, a private, nonprofit organisation that evaluates the clinical and economic value of prescription drugs, ...
Posted by Michael Wonder on 05 Nov 2018
Novartis says SMA gene therapy is cost-effective at $4-5 million per patient
5 November 2018 - Novartis, which is shifting into rare diseases, said on Monday it believes its new gene therapy ...
Posted by Michael Wonder on 30 Oct 2018
Analysis of base-case ICERs accepted by the PBAC (July 2018)
30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 13 Oct 2018
Long-term survival and value of chimeric antigen receptor T-cell therapy for paediatric patients with relapsed or refractory leukaemia
8 October 2018 - What is the long-term survival and value of tisagenlecleucel for paediatric patients with relapsed or refractory leukaemia? ...
Posted by Michael Wonder on 11 Oct 2018
New value assessment framework needed for biosimilars, white paper argues
11 October 2018 - As US healthcare increasingly moves toward value-based payment approaches, biosimilars, which reduce costs while maintaining treatment quality, ...
Posted by Michael Wonder on 10 Oct 2018
New drugs: how much are governments paying for innovation?
10 October 2018 - The medical innovation debate is also heated up due to the ongoing discussion on Health Technology Assessments. ...
Posted by Michael Wonder on 02 Oct 2018
A payer’s perspective on value-based contracting
1 October 2018 - What payer wouldn’t want to ensure that they pay for value when buying drugs? If the ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 27 Sep 2018
Paying for value: US state of play
27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the ...
Posted by Michael Wonder on 19 Sep 2018
Payment and delivery system reform — the next phase
19 September 2018 - After nearly a decade of experimentation with value-based payment, U.S. health care payers, providers, and purchasers are ...
Posted by Michael Wonder on 15 Sep 2018
Patient groups attack CVS use of ICER metrics, urge rethink
14 September 2018 - More than 90 organisations, predominantly patient groups, criticised CVS Caremark's decision last month to incorporate value-based drug ...